Role of Granulocyte Colony-Stimulating Factor in the Management of Infection with Fusarium oxysporum in a Neutropenic Child

Hennequin, Claire; Benkerrou, Malika; Jl, Gaillard; Blanche, S.; Fraïtag, Sylvie

doi:10.1093/clinids/18.3.490

Cited by 34 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decreasing of immunosuppression should be attempted in patients with prior history of Fusarium infection and can be achieved by a reduction in or discontinuation of immunosuppressive agents, shortening the duration of neutropenia (selection of nonmyeloablative as opposed to myeloablative preparative regimens for allogeneic HSCT and the use of preemptive G-CSF-elicited or G-CSF-and dexamethasone-elicited white blood cell transfusions) (22,46). If the organism is available, antifungal susceptibility testing should be performed and antifungal prophylaxis with an agent active against the recovered fusarial strain should be considered.…”

Section: Preventionmentioning

confidence: 99%

Fusarium Infections in Immunocompromised Patients

2007

View full text Add to dashboard Cite

SUMMARY Fusarium species cause a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections. The clinical form of fusariosis depends largely on the immune status of the host and the portal of entry, with superficial and localized disease occurring mostly in immunocompetent patients and invasive and disseminated disease affecting immunocompromised patients. Risk factors for severe fusariosis include prolonged neutropenia and T-cell immunodeficiency, especially in hematopoietic stem cell transplant recipients with severe graft-versus-host disease. The most frequent presentation of disseminated fusariosis is a combination of characteristic cutaneous lesions and positive blood cultures, with or without lung or sinus involvement. The prognosis is poor and is determined largely by degree of immunosuppression and extent of infection, with virtually a 100% death rate among persistently neutropenic patients with disseminated disease. These infections may be clinically suspected on the basis of a constellation of clinical and laboratory findings, which should lead to prompt therapy. Treatment options include the lipid formulations of amphotericin B, voriconazole, and posaconazole. Prevention of fusarial infection among high-risk patients should be considered.

show abstract

Section: Preventionmentioning

confidence: 99%

Fusarium Infections in Immunocompromised Patients

2007

View full text Add to dashboard Cite

show abstract

“…The mortality attributable to Fusarium infections in immunocompromised patients ranges from 50% to 70% [2,14,23,24]. Persistence of severe immunosuppression and particularly neutropenia is the most important factor associated with the poor outcome of patients with invasive fusariosis [4,21,25].…”

Section: Clinical Spectrummentioning

confidence: 99%

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

Tortorano

Richardson

Roilides³

et al. 2014

Clinical Microbiology and Infection

413

401

View full text Add to dashboard Cite

Mycoses summarized in the hyalohyphomycosis group are heterogeneous, defined by the presence of hyaline (non-dematiaceous) hyphae. The number of organisms implicated in hyalohyphomycosis is increasing and the most clinically important species belong to the genera Fusarium, Scedosporium, Acremonium, Scopulariopsis, Purpureocillium and Paecilomyces. Severely immunocompromised patients are particularly vulnerable to infection, and clinical manifestations range from colonization to chronic localized lesions to acute invasive and/or disseminated diseases. Diagnosis usually requires isolation and identification of the infecting pathogen. A poor prognosis is associated with fusariosis and early therapy of localized disease is important to prevent progression to a more aggressive or disseminated infection. Therapy should include voriconazole and surgical debridement where possible or posaconazole as salvage treatment. Voriconazole represents the first-line treatment of infections due to members of the genus Scedosporium. For Acremonium spp., Scopulariopsis spp., Purpureocillium spp. and Paecilomyces spp. the optimal antifungal treatment has not been established. Management usually consists of surgery and antifungal treatment, depending on the clinical presentation.

show abstract

“…Of all the other factors, recovery of neutrophils is of prime importance, without which this infection remains fatal (Boutati & Anaissie, 1997 help to limit the infection and stop or delay dissemination to other parts of the body (Lupinetti et al, 1990(Lupinetti et al, , 1992Robertson et al, 1991;Ellis et al, 1994). The use of granulocyte infusions in selected cases and growth factors to enhance and expedite neutrophil recovery also play a positive role in reducing fatalities (Spielberger et al, 1993;Ellis et al, 1994;Hannequin et al, 1994).…”

mentioning

confidence: 99%

The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non‐immunocompromised patients: a single institution experience over 10 years

Musa¹,

Eisa²,

Halim

et al. 2000

Br J Haematol

View full text Add to dashboard Cite

Summary. Fusarium is a newly emerging fungal pathogen associated with signi®cant morbidity and mortality in the immunocompromised host. We have reviewed our hospital's experience with Fusarium between 1985 and 1995. Fusarium species were isolated from 22 specimens, representing 11 patients. Cases were not clustered by time period. The median age of the patients was 36´5 years (range 17±69 years). The sources of the organism were 12 skin lesions from eight patients, seven blood cultures from two patients and one specimen each from a Hickman catheter tip, nail clippings and a bronchoalveolar lavage. Seven of the patients had chemotherapy-induced neutropenia when the Fusarium was isolated. Five of them developed invasive fusarosis during acute leukaemia induction treatment. They remained neutropenic, and none survived. The other two patients recovered from neutropenia and were treated successfully for this infection. The remaining four patients were not neutropenic or immunocompromised. Three grew Fusarium from skin or nail clippings and one from bronchial alveolar lavage (BAL). There was no evidence of invasive disease in any of the four. None of them received antifungal therapy, and they were all alive at last follow-up. We conclude that Fusarium is a newly emerging infection in neutropenic patients. A high index of suspicion, especially for skin lesions, will help in early diagnosis before systemic and visceral dissemination. Excision of the initial focus of infection and antifungal therapy, aided by speedy neutrophil recovery, are likely to protect patients threatened with these fatal infections. Fusarium isolated from non-neutropenic, nonimmunosuppressed patients is not signi®cant and does not merit systemic antifungal treatment.

show abstract

Role of Granulocyte Colony-Stimulating Factor in the Management of Infection with Fusarium oxysporum in a Neutropenic Child

Cited by 34 publications

References 0 publications

Fusarium Infections in Immunocompromised Patients

Fusarium Infections in Immunocompromised Patients

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non‐immunocompromised patients: a single institution experience over 10 years

Contact Info

Product

Resources

About